NanoVibronix Inc
For the period ended Dec 31, 2023. Filed Apr 8, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2023 · Filed Apr 8, 2024
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
SIGNATURES
Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
| NANOVIBRONIX, INC. | |
| By: | /s/ Brian Murphy |
| Brian Murphy | |
| Chief Executive Officer (Principal Executive Officer) | |
| Date: | April 8, 2024 |
| By: | /s/ Stephen Brown |
| Stephen Brown | |
| Chief Financial Officer (Principal Financial and Accounting Officer) | |
| Date: | April 8, 2024 |
POWER OF ATTORNEY
KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below constitutes and appoints Brian Murphy as his true and lawful attorneys-in-fact and agents, with full power of substitution and re-substitution, for him and in his name, place and stead, in any and all capacities, to sign any and all amendments to this Form 10-K, and to file the same, with all exhibits thereto, and other documents in connection therewith, with the SEC, granting unto said attorneys-in-fact and agents, and each of them, full power and authority to do and perform each and every act and thing requisite and necessary to be done in connection therewith, as fully to all intents and purposes as he might or could do in person, hereby ratifying and confirming that all said attorneys-in-fact and agents, or any of them or their or his substitute or substitutes, may lawfully do or cause to be done by virtue hereof.
Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the Registrant and in the capacities and on the dates indicated.
| Signature | Title | Date |
|---|---|---|
| /s/ BRIAN MURPHY | Chief Executive Officer and Director | April 8, 2024 |
| Brian Murphy | (principal executive officer) | |
| /s/ STEPHEN BROWN | Chief Financial Officer | April 8, 2024 |
| Stephen Brown | (principal financial and accounting officer) | |
| /s/ CHRISTOPHER FASHEK | Chairman of the Board of Directors | April 8, 2024 |
| Christopher Fashek | ||
| /s/ MARTIN GOLDSTEIN | Director | April 8, 2024 |
| Martin Goldstein | ||
| /s/ HAROLD JACOB M.D. | Director | April 8, 2024 |
| Harold Jacob, M.D. | ||
| /s/ MICHAEL FERGUSON | Director | April 8, 2024 |
| Michael Ferguson | ||
| /s/ THOMAS R. MIKA | Director | April 8, 2024 |
| Thomas R. Mika | ||
| /s/ Aurora Cassirer | Director | April 8, 2024 |
| Aurora Cassirer | ||
| /s/ Maria Schroeder | Director | April 8, 2024 |
| Maria Schroeder | ||
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.